Literature DB >> 26825732

Alteration of STR profiles in ovarian carcinoma cells during primary culture.

Xiufeng Huang1,2, Jörg Weimer3, Nicole von Wurmb-Schwark4, Regina Fredrik2, Norbert Arnold2, Christian Schem2.   

Abstract

PURPOSE: Cell authentication is a necessary procedure to avoid scientific data from cell culture experiments with cross-contamination or false classification. A genetic fingerprint pattern of a specimen by short tandem repeats (STR) is self-evident. Due to high amount of chromosomal rearrangements, known in epithelia ovary cancer cells and the instable STR pattern described in other tumour entities like leukaemia, this study explores the suitability of STR profiling for primary cultured epithelial ovary cancer cells.
METHODS: STR profiles of epithelial ovary cancers of 16 patients were compared with corresponding blood and corresponding primary cell cultures. The primary cell cultures of epithelial ovary tumours were passaged up to 28 times. In between, cultures were cryo conserved and recultured again, two to five times per patient.
RESULTS: In two cases, the STR pattern of tumour lost alleles (1/16 and 3/16) in comparison of corresponding STR-pattern from blood. In comparison to blood, cell culture of a third case, lost four alleles (4/16) accompanied with morphologic changes after 14th passage. It is equal after cryo conservation of the seventh passage from the same patient. The only changes in STR profiles we recognized are losses of alleles. Remaining STR markers allow authentication.
CONCLUSIONS: Very likely, the allelic drop-outs beyond passage 14 assume complex genetic losses of heterozygosis resulting in changed growth behaviour of cells. All other STR-profiles of remaining 15 patients analysed in this study are stable over all passages and freeze-thaw processes. Thus, ovary cancer cell cultures in research should be authenticated by STR-profile in general.

Entities:  

Keywords:  Authentication; Cross-contamination; Genetic fingerprint; Primary ovary cancer cell culture; STR profiling

Mesh:

Year:  2016        PMID: 26825732     DOI: 10.1007/s00404-016-4018-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  The Tumorgenicity of Glioblastoma Cell Line U87MG Decreased During Serial In Vitro Passage.

Authors:  Yu Zeng; Xizhao Wang; Jizhou Wang; Renhui Yi; Hao Long; Mingfeng Zhou; Qisheng Luo; Zhihao Zhai; Ye Song; Songtao Qi
Journal:  Cell Mol Neurobiol       Date:  2018-06-08       Impact factor: 5.046

2.  ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids.

Authors:  Nina Hedemann; Andreas Herz; Jan Hendrik Schiepanski; Jan Dittrich; Susanne Sebens; Astrid Dempfle; Julia Feuerborn; Christoph Rogmans; Nils Tribian; Inken Flörkemeier; Jörg Weimer; Sandra Krüger; Nicolai Maass; Dirk O Bauerschlag
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

3.  ADAM17 inhibition enhances platinum efficiency in ovarian cancer.

Authors:  Nina Hedemann; Christoph Rogmans; Susanne Sebens; Daniela Wesch; Manuel Reichert; Dirk Schmidt-Arras; Hans-Heinrich Oberg; Ulrich Pecks; Marion van Mackelenbergh; Jörg Weimer; Norbert Arnold; Nicolai Maass; Dirk O Bauerschlag
Journal:  Oncotarget       Date:  2018-03-23

4.  High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer.

Authors:  Inken Flörkemeier; Tamara N Steinhauer; Nina Hedemann; Jörg Paul Weimer; Christoph Rogmans; Marion T van Mackelenbergh; Nicolai Maass; Bernd Clement; Dirk O Bauerschlag
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

5.  Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.

Authors:  Inken Flörkemeier; Tamara N Steinhauer; Nina Hedemann; Magnus Ölander; Per Artursson; Bernd Clement; Dirk O Bauerschlag
Journal:  Ther Adv Med Oncol       Date:  2021-11-25       Impact factor: 8.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.